APA

Friedland G. H., Pollard R., Griffith B., Hughes M., Morse G., Bassett R., Freimuth W., Demeter L., Connick E., Nevin T., Hirsch M. & Fischl M. (19990809). Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. : Journal of acquired immune deficiency syndromes (1999).

Chicago

Friedland G H, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M and Fischl M. 19990809. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. : Journal of acquired immune deficiency syndromes (1999).

Harvard

Friedland G. H., Pollard R., Griffith B., Hughes M., Morse G., Bassett R., Freimuth W., Demeter L., Connick E., Nevin T., Hirsch M. and Fischl M. (19990809). Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. : Journal of acquired immune deficiency syndromes (1999).

MLA

Friedland G H, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M and Fischl M. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. : Journal of acquired immune deficiency syndromes (1999). 19990809.